Genetic polymorphisms of collagen type I α1 chain (COL1A1) gene increase the frequency of low bone mineral density in the subgroup of children with juvenile idiopathic arthritis by Mikhail M Kostik et al.
Kostik et al. The EPMA Journal 2013, 4:15
http://www.epmajournal.com/content/4/1/15RESEARCH Open AccessGenetic polymorphisms of collagen type I α1 chain
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mineral density in the subgroup of children with
juvenile idiopathic arthritis
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Background: Collagen type I is one of the key proteins involved in the maturation, development and
mineralization of bone. Genetic polymorphisms of collagen type I alpha-1 chain (COL1A1) gene are associated with
low bone mineral density and higher risk of fractures in adults and children. We hypothesize that the polymorphic
alleles and genotypes of COL1A1 gene influence bone mineralization and metabolism in children with juvenile
idiopathic arthritis (JIA).
Methods: We recruited 196 children with JIA in our study. Bone mineral density (BMD) was measured by lumbar
spine dual-energy X-ray absorptiometry. Osteocalcin, Ca, Ca2+ and inorganic phosphate (Pi) were utilized for the
assessment of bone metabolism. Molecular testing: Sp1 (rs1800012) and -1997G/T (rs1107946) polymorphisms of
COL1A1 gene were detected RFLP.
Results: No differences in genotype, allele and haplotype distribution of COL1A1 were detected among children
with normal and low BMD (LBMD; <−2 standard deviation). The presence of GG genotype of Sp1 increased the
incidence of LBMD in Tanner II to III children (odds ratio (OR) = 9.7 [95% confidence interval (CI), 1.2; 81.7], p = 0.02) as
well as GG genotype of -1997G/T increased the frequency of LBMD in Tanner IV to V children (OR = 4.5 [95% CI, 0.9; 22.0],
p = 0.048). Tanner I children with -1997GG genotype had lower Ca2+ and osteocalcin and higher Pi compared with
carriers of -1997Т allele. Tanner IV to V children with -1997GG genotype had lower BMD and BMD-Z score than carriers
of -1997Т.
Conclusions: The evaluation of the biologic effects of the GG Sp1 and GG of -1997G/T polymorphism of COL1A1 has
shown negative effect on BMD and mineral turnover related to pubertal stage.
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Children with juvenile idiopathic arthritis (JIA) have
disturbances in bone mineralization which are realized
in the lack of bone mineral accrual, growth delay and
fractures [1-4]. In JIA patients, factors that impact bone
metabolism include the subtype of arthritis, disease* Correspondence: kost-mikhail@yandex.ru
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reproduction in any medium, provided the orduration, concomitant treatment with systemic steroids
and disease activity [5,6]. However, there is no strict
relationship between negative factors that impact bone
mineralization and bone damage [5,7]. Some patients
quickly decrease bone mineralization, realize fractures
and do it very quickly, while others are still resistant to
negative factors that influence bone health [8,9]. Indeed,
the rate of bone loss or lack of bone mineral gain depends
on the combination of environmental (disease and
physical activity, diet) and genetic factors involved in
bone metabolism. The knowledge about the factorstd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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to select appropriate treatment and preventive program
in JIA patients with high risk of bone damage [10-15].
There are only few studies about the possible role of
genetic factors in bone metabolism [16]. Unfortunately,
reported studies are difficult to compare due to the
differences in the studied population, subgroups of
arthritis, disease duration, concomitant treatment and
definition of bone health damage. Difficulties in the
interpretation of the prognostic role of genetic factor in
the prevention of bone damage in JIA patients lead to
these genetic factors to be rarely studied. One of the
well-studied and clinically significant genetic factors
that influence bone mineralization is collagen type I.
Collagen type I is one of the key proteins associated
with bone quality, strength and health, because this is a
main protein of the bone organic matrix involved in
bone maturation, development and mineralization [17].
The most striking example is osteogenesis imperfecta, in
which mutations in genes, encoding different types of
collagen invoke more than 90% of patients, lead to low
bone mineralization and frequent fractures [18]. Not only
mutations but also genetic polymorphisms of collagen
type I alpha-1 chain (COL1A1) gene are also associated
with low bone mineral density and higher risk of fractures
in adults and children [19,20]. The same genotypes
influence on the risk of ligaments and tendon injuries,
joint dislocations and formation of lumbar disk disease
[21-23]. Sp1 polymorphism is located in the intronic part
of COL1A1 gene, associated with transcription start site,
and -1997G/T polymorphism is located in promoter
region of this gene. These polymorphisms affect on DNA
banding affinity of transcription factors involved in bone
metabolism, such as Nmp4, Osterix and Sp1. Functional
activity of polymorphic genotypes is associated with
increased transcription activity and enhanced collagen
synthesis that leads to misbalance in normal alpha-1
and alpha-2 chain ratio (2:1) of collagen type I and realized
in disturbances of bone mineralization and fall of bone
strength [24]. Normally, carriers of SS (GG) genotype have
normal alpha-1 and alpha-2 chain ratio (1.99±0.07 to 1.0)
of collagen type I, but heterozygous have increased alpha-1
and alpha-2 chain ratio (2.36±0.1 to 1.0). Excessive
synthesis of alpha-1 chains leads to the formation of
molecules of collagen consist of three alpha-1 chains -
heterotrimers [α1(I)3], characterized by abnormal precipi-
tation of inorganic salts. Carriers of Ss (GT) genotype have
less inorganic and more organic components of bone that
affect bone strength and mineralization [25]. Bone biopsy
exposed that GT carriers had lower mineralization and
impressive heterogeneity compare with GG carriers of
Sp1 COL1A1. In vitro studies have revealed low osteoblast
activity to form sites of bone mineralization in GT carriers
which also affects bone strength [26].The objective of the present study was to investigate
the role of Sp1 and -1997G/T genetic polymorphisms of
the COL1A1 gene in bone mineralization and turnover
in children with JIA.
The biggest meta-analysis which covered 24,511 partici-
pants including results of 32 studies shows that TTgenotype
of COL1A1 Sp1 polymorphism is associated with the
modest reduction of hip (0.16 units, p = 1 × 10−6)
and lumbar spine (LS) bone mineral density (BMD)
(0.13 units, p = 0.01) and increased risk of fractures
(1.31-fold, p = 0.02) in the whole group and in the
subgroup of females as compared to GG carriers. No
differences in males were observed. Borderline significance
was observed between LS BMD of -1997GG homozygotes
and carriers of the T allele (GT+TT). In females, LS
BMD values were lower (0.06 units, p = 0.02) in the GG
homozygotes as compared with G/T heterozygotes. No
associations with genotypes and BMD in males and no
association with fracture risk in whole group and subgroups
were observed [27]. The results in the studies included in
this meta-analysis were controversial.
The presence of ss (TT) genotype was associated with
low BMD without increased fracture rate in Greek post-
menopausal women [28] and in French premenopausal
women [29]. Braga et al. in a group of perimenopausal
and postmenopausal women showed that ss genotype is
associated with the lowest BMD levels in hip and LS,
but they also determined the age-related effect of poly-
morphic genotypes. The effect of COLIA1 was not visible
until the sixth decade of life, but it increased thereafter
with aging, becoming statistically significant also at the
lumbar spine in subjects aged >70 years. The authors
suggest that this polymorphism is more related with
age-dependent bone loss than with peak bone mass [30].
Both reduced BMD and increased risk of fractures
were observed in ss genotype carriers in several studies.
Keen et al. have shown association of ss genotype with
the reduction of LS BMD, increased risk of fractures and
increased urinary pyridinoline [31]. McGuigan et al. did
not find any significant difference in bone density, rate of
bone loss, body weight, height or years since menopause
between the COL1A1 genotype groups but have revealed
that s allele is an independent predictor of fractures only
in women. The incidence of fractures was 45 times higher
in those with low BMD who carried ‘s’ allele [32]. In the
study of Bernad et al., the frequency of TT (ss) genotype
was significantly higher in osteoporotic postmenopausal
women than in non-osteoporotic and in osteoporotic
women with fractures compare with non-fracture females,
odds ratio (OR) for fractures = 5.9 for TT compared with
GG+GT genotypes [33]. The similar results were observed
in a group of 1,044 75-year-old Swedish women. The pres-
ence of at least one copy of the ‘s’ allele was associated
with lower femoral neck (FN) BMD and increased risk of
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for the Ss heterozygotes when compared with the SS
homozygotes [34].
The results of some studies did not find any association
of polymorphic genotypes with BMD in the group of post-
menopausal women [35,36] in pre- and perimenopausal
women [37].
In contrast, some studies have not revsealed relations
between Sp1 COLIA1 and lumbar spine and femoral neck
BMD in Irish females before and after menopause [38], in
UK females elder than 75 years in bone mineralization
and fractures prevention [39] and in Chinese males and
females [40]. In 100 Chinese, Sp1 polymorphism was not
found, and the authors suggest that the absence of such
relation is typical for Asians, described earlier [40].
In longitudinal 18-year study about the relation of
BMD loss and Sp1 COLIA1 polymorphic genotypes in
postmenopausal females, there were no difference in
lumbar spine and femoral neck BMD loss due to poly-
morphic genotypes. Patients with Ss and ss genotypes of
Sp1 COLIA1, considering a lot of researches, have to have
lower BMD, in practice, in this study had higher forearm
BMD than SS genotype carriers, that is, controversial to
the results of study described earlier. The authors didnot
support the hypothesis that Ss COLIA1 genotype predis-
poses to increased ranges of BMD loss and low BMD [41].
Opposite results were detected in patients with somatic
diseases. In Hungarian patients with primary biliary
cirrhosis and high percentage of osteoporosis, there was a
lower frequency of s allele Sp1 COLIA1 than in controls.
There were no differences in mineralization in patients
with polymorphic genotypes [42]. Perhaps, it is possible
that due to the influence of pathogenic disease factors on
BMD, and interactions between genes and disease.
Few pediatric studies show controversial results, as
well as in adults. In a Norwegian study that included
269 healthy boys and girls over the 4 years old, there
were no differences in mineralization with polymorphic
genotypes, excluding a small group of boys with ss geno-
type Sp1 COLIA1 who had higher femoral neck BMD
compare with SS and Ss [43]. Possibly, it could be due to
the different ages of children included in study, and
separate analysis in children of equal age and pubertal
development has not been performed. In the study carried
out in Los Angeles, vertebra mineralization and size were
evaluated in 109 prepubertal Mexican girls. Revealed
changes are equal to the majority of adult's studies: girls
with SS genotype Sp1 COLIA1 had higher BMD than in
girls that are carriers of s allele (Ss and ss). There were no
significant differences in vertebra size in girls with poly-
morphic genotypes [44]. In the largest pediatric study,
performed in UK, the analysis of the role of Sp1 COL1A1
and Pvull COL1A2 polymorphic genotypes on fracture
risk (FR) was carried out separately, depending on gender,fracture site and pubertal stage. The presence of s allele
Sp1 COL1A1 was associated with increased FR (OR = 3.1
[95% confidence interval (CI) 1.43 to 6.61], p = 0.004)
only in prepubertal children (Tanner I). In mid-pubertal
and pubertal children, polymorphic genotypes did not
relate with FR. Also, there were no differences in bone
mineralization in children with polymorphic genotypes in
any of studied groups [19]. In a group of 258 prepubertal
Caucasian children from Australia, there were no associa-
tions between Sp1 binding site of the COLIA1 polymorphic
genotypes, and v-BMD of FN and LS were found [45].
Among Turkish children with forma magna of β-thalas-
semia and osteoporosis, the s allele of Sp1 COLIA1 was
more frequent than in controls (healthy adults without
osteoporosis), but the highest BMD-Z score in the
lumbar spine was in carriers of s allele (ss>Ss>SS). Opposite
it, patients with SS genotype had the highest




Approval was obtained from the Saint-Petersburg State
Pediatric Medical University committee on the ethics of
research on human beings. Blood samples were obtained
after informed written consent. All specimens for the labs
were collected at the same time as the DNA specimens.
One hundred ninety-six children with JIA were enrolled
in the study between January 2003 and December 2007.
Each child was a patient of the Saint-Petersburg State
Pediatric Medical University rheumatology clinic. All
patients were Caucasians. We enrolled all patients who
fulfilled the European League Against Rheumatism JIA
criteria and agreed to take part in our study [47]. Only one
child per family was enrolled. All patients were divided into
three groups according to arthritis course: oligoarticular,
polyarticular and systemic arthritis. Extended oligoarticular
patients and systemic arthritis patients without signs of
systemic activity were included in polyarticular group.
Exclusion criteria were children with any serious
gastrointestinal problems, malabsorption, liver diseases,
alimentary and other known types of dystrophy. Children
who had received hormone replacement therapy (estrogens,
oral contraceptive) or had disease known to affect bone
metabolism (diabetes mellitus and others endocrinopathy,
skeletal dysplasia, rickets-like diseases) and children with
non-traumatic fractures in whom idiopathic osteoporosis
could be suspected also were excluded. Supplementation
of calcium and vitamin D was allowed only for children,
who were treated by corticosteroids (CS). Non-CS children
were excluded if they had calcium and vitamin D
supplementation in the previous 3 months before
study enrollment. No patients with biologic treatment
were included in the present study.
Table 1 Demographics of JIA patients included in the
present study
Parameters JIA patients, n = 198
Age, yearsa 12.0 (7.0; 15.0)
Girls/boys, n (%) 116 (58.6)/82 (41.4)
Height, cma 154.5 (123.3; 165.0)
Height<10th%, n (%) 14 (7.1)
Weight, kga 42.0 (25.0; 55.0)
Weight<10th%, n (%) 27 (13.6)
BMIa
Moderate and severe thinness (BMI ≤ 17.0), n (%) 17.35 (15.6; 20.1)
Underweight (17.0 < BMI ≤ 18.5), n (%) 87 (43.9)
Normal (18.5 < BMI < 25.0), n (%) 35 (17.7)
Pre-obese (25.0 ≤ BMI < 30.0), n (%) 62 (31.3)
Obese (BMI ≥ 30.0), n (%) 12 (6.1)
Puberty stage, Tanner 2 (1.0)
Pre-pubertal (I) 71 (35.9)
Mid-puberty (II to III) 54 (27.3)
Pubertal (IV to V) 73 (36.9)




Onset age, yearsa 7.0 (3.9; 12.0)
Disease duration, yeara 2.0 (0.5; 2.0)
Active joints, n 2.0 (1.0; 6.0)
ESR, mm/ha 6.0 (4.0; 25.0)
CRP, mg\la 5.0 (2.2; 18.0)
Glucocorticoides, n (%) 52 (26.3)
DMARD, n (%) 81 (40.9)
LBMD, n (%) 44 (22.2)
Fractures (vertebral and non-vertebral), n (%) 29 (14.6)
aMe (IQR).
Table 2 JIA patients with Sp1 and -1997G/T polymorphic gen
Population Genotype LBM
Sp1
All JIA patients (n = 196) ‘GG’ 30 (6
‘GT’ 13 (3
‘TT’ 0 (0.
JIA patients in Tanner stages II to III (n = 54) ‘GG’ 14 (9
‘GT’ and ‘TT’ 1 (6.
−1997G/T
All JIA patients (n = 188) ‘GG’ 28 (6
‘GT’ 12 (2
‘TT’ 2 (4.
JIA patients in Tanner stages IV to V (n = 70) ‘GG’ 12 (2
‘GT’ and ‘TT’ 32 (7
aFisher's exact test.
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Bone mineralization was measured in 196 patients by
dual-energy X-ray absorptiometry of lumbar spine at
L1-L4 (Hologic QDR 4500C densitometer with reference
pediatric database, Hologic Inc., Bedford, MA, USA).
Densitometry parameters, such as bone area (cm2), bone
mineral content (g) and BMD (measured in g/cm2 and in
Z score, standard deviation (SD)), were all evaluated. Low
bone mineral density (LBMD) for chronological age was
defined by Z score < 2 SD, according to the recommenda-
tion of the International Society for Clinical Densitometry
2007 [48].
For the assessment of bone metabolism the following
measures were used: osteocalcin (bone gla-protein, a
marker of osteosynthesis) using immunochemiluminiscent
assay. Also, levels of total and ionized calcium (Ca++) and
inorganic phosphate were determined.
Genetic analysis
For the detection of COL1A1 Sp1 (rs1800012) and -
1997G/T (rs1107946) polymorphisms, the previously
published method [49,50] was used. After the treatment
of PCR product containing Sp1 polymorphism by Bse1I
endonuclease following DNA fragments were generated:
63 and 22 bp for Sp1 G allele, 85 bp for Sp1 T allele.
PCR product containing -1997G/T polymorphism was
treated by BstMAI endonuclease whereupon following
DNA fragments were generated: 275 and 58 bp for -
1997G allele, 333 bp for -1997T allele. The size of DNA
fragments was estimated using polyacrylamide gel elec-
trophoresis. One hundred ninety-six and 188 patients
were analyzed for Sp1 and -1997G/T polymorphisms,
respectively.
Statistical analysis
Associations between the COL1A1 polymorphisms and
bone mineralization and bone metabolic markers in JIAotypes, divided according to LBMD and pubertal stage
D NBMD OR [95% CI], ‘GG’ baseline p
9.8) 107 (69.9) 0.75
0.2) 44 (28.8)
0) 2 (1.3)
3.3) 23 (59.0) 9.7 [1.2; 81.7], sensitivity −0.93, 0.02a
7) 16 (41.0) Specificity - 0.41
6.7) 96 (65.7) 0.77
8.6) 46 (31.5)
7) 4 (2.8)
7.3) 2 (7.7) 4.5 [0.9; 22.0], sensitivity −0.27, 0.048
2.7) 24 (92.3) Specificity - 0.92
Table 3 Parameters of bone metabolism, mineralization and mineral turnover related to pubertal stage and -1997G/T
Col1A1 polymorphic genotypes
Population Parameter ‘GG’ ‘GT’ and ‘TT’ p
JIA patients in Tanner stage I (n = 68) Ca++, mmol/l 1.12 (1.05; 1.17) 1.15 (1.1; 1.2) 0.03
Pi, mmol/l 1.67 (1.56; 1.73) 1.6 (1.47; 1.63) 0.03
osteocalcin, ng/ml 81.4 (66.8; 95.6) 108.3 (105.4; 120.4) 0.02
JIA patients in Tanner stage IV to V (n = 70) BMD, g/cm2 0.84 (0.76; 0.93) 0.91 (0.88; 0.96) 0.03
BMD-Z score, SD −1.29 (−2.1; −0.57) −0.65 (−1.14; 0.39) 0.009
Kostik et al. The EPMA Journal 2013, 4:15 Page 5 of 8
http://www.epmajournal.com/content/4/1/15patients were analyzed using Statistica 6.0 (StatSoft,
Tulsa, OK, USA). We utilized chi-square test, Fisher's
exact test and Mann–Whitney analysis. Data are shown
in median and quartiles (Me; 25%; 75%). Because we had
a restricted number of JIA children with -1997ТТ and
Sp1 TT genotypes for statistical analysis, all children were
divided in two groups: carriers of the T allele (GT+TT
genotypes) and carriers of GG genotype (no T allele).
P values < 0.05 were considered to indicate a significant
difference. No significant differences in anthropometry
and disease activity status related to COL1A1 polymor-
phisms were found.
Results
The main demographic and clinical features of study
patients were shown in Table 1. We had no differences
in genotype distribution in the group with growth delay
(linear growth <10th percentile) compare with JIA children
with normal linear growth (25th to 75th percentile).
Also, we compared genotype distribution between
children with growth delay (<10th percentile) with children
with increased linear growth (>90th percentile), and no
differences were observed. Thus, these two polymorphic
markers are not associated with linear growth in our
cohort.
The analysis of distribution of genotypes, alleles and
haplotypes of COL1A1 has not revealed differences
among children with normal and LBMD. In pubertal
subgroups, some differences were observed.
Prepubertal children (Tanner I) had changes of some
parameters of bone metabolism and mineral turnover
associated with -1997G/T COL1A1 polymorphic alleles and
genotypes. Children with -1997GG genotype compared
with carriers of -1997Т allele had lower Ca++, osteocalcin
and higher inorganic phosphate. The presence of -
1997GG in prepubertal children was associated with lowerTable 4 Comparison of the distribution of Sp1 genotypes of C
Genotypes Berg et al. 2000 Sainz et al. 1999 Blades et al. 201
GG (SS) 197 (73.2) 86 (78.8) 124 (67.0)
GT (Ss) 61 (22.7) 22 (20.1) 54 (30.0)
TT (ss) 11 (4.1) 1 (0.9) 5 (3.0)
p (vs. our study) 0.05 0.23 0.46bone turnover without the impact of bone mineralization
and frequency of LBMD and fracture rate.
In early to mid-puberty children, i.e., Tanner stages II
to III, the presence of the GG genotype of Sp1 Col1A1
leads to the increased incidence of LBMD. In pubertal
children, who nearly completed growth, i.e., Tanner stage
IV to V associations with other polymorphic genotypes
were observed. Pubertal children with -1997GG genotype
had lower BMD, BMD-Z score and increase frequency
LBMD than carriers of -1997Т (Tables 2 and 3). No differ-
ences in parameters of bone metabolism and mineral
turnover related to Sp1 polymorphic genotypes in pubertal
subgroup were observed.
We focused the association between COL1A1 genotypes
and bone mineral density and metabolism in the subgroup
of children with JIA according Tanner stage. Disease activity,
lack of locomotion and concomitant treatment are the
main damage factors of bone health and linear growth in
JIA children. In relation to bone status, the JIA population
is quite heterogenous due to different arthritis subtypes,
number of active joints, disease duration, dosage and kind
of treatment, age of affected children and puberty status.
Some JIA patients have increased bone sensitivity and
susceptibility to negative factors related to age, puberty
and perhaps, to genetic background. The sequence of
bone mineral and metabolic disturbances due to puberty
stage and genotype was observed in our study. Prepubertal
children had only decreased rate of bone turnover without
changes of BMD, but children with advanced Tanner
stages had already decreased bone mineralization. The
results of our study had some controversies compared to
previous studies. Some different ethnic populations and
differences in genotype distributions can provide the
contrasts of results. In our study, GG (SS) genotype is
associated with LBMD. Similar results were described
before Berg et al. [47] and Guzeloglu-Kayisli et al. [50] inOLIA1 gene in different populations
0 Tao et al. 1999 Guzeloglu-Kayisli et al. 2008 Our study p
92 (66.7) 77 (84.0) 137 (69.9) 0.02
40 (29.0) 15 (16.0) 57 (29.1)
6 (4.3) 0 (0.0) 2 (1.0)
0.14 0.036 - -
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Comparison of genotype distribution has revealed sig-
nificant differences between the results of our study and
studies with similar results. The highest frequency of TT
(ss) genotype was observed in the work of Berg et al. and
the highest frequency of GG in Guzeloglu-Kayisliet al.
The data of genotype distributions in previous and our
studies are shown in Table 4. The results of previous
studies do not give as a clear answer to the question which
of the COLIA1 polymorphism is more related to bone
mass in both adult and children populations. Controversial
results could be explained by the features of individuals
(healthy or ill), racial and national differences, type of data
analysis considering interfere of gender, age, pubertal
stage and any others environmental factors which are
accompanied with gene-gene interactions. The results
of our study have limitations related to interaction of
environmental and genetic factors and heterogeneity of
studied population (age, puberty, disease parameters).Conclusions
The evaluation of biologic effects of GG Sp1 and GG of -
1997G/T polymorphism of COL1A1 has shown negative
effect on bone mineralization and some markers of bone
metabolism and mineral turnover related to pubertal stage.
1. The presence of GG genotype of Sp1 COL1A1
increased the risk of LBMD in mid-puberty JIA
children.
2. Pubertal children with -1997GG genotype
COL1A1had lower BMD and BMD-Z score than
carriers of -1997Т allele. The presence of -1997GG
genotype increased the frequency of LBMD.
3. Prepubertal children with -1997GG genotype had
lower ionized calcium, osteocalcin and higher
inorganic phosphate as compared with carriers
of -1997Т allele carriers.Expert recommendations
The testing of genetic polymorphism can detect the target
population of children with JIA who are more susceptible
to the development of bone mineral disorders. Also, we
suggest that genetic polymorphisms can play the adaptive
role in bone mineralization and turnover regulating into
different age intervals.
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